Vanquish
Phase 2- Indications
- Prostate cancer
Company intelligence / Profile preview
Francis Medical’s Vanquish Water Vapor Ablation System has shown promising results in early feasibility and pivotal studies for the treatment of intermediate-risk localized prostate cancer. The VAPOR 1 Early Feasibility Study met its six-month primary endpoints with positive safety and efficacy data published in peer-reviewed journals. The VAPOR 2 pivotal study completed enrollment ahead of schedule in February 2025; FDA Breakthrough Device Designation was granted to Vanquish in August 2023 to expedite review and access.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Francis Medical.